TARA - NASDAQ
Protara Therapeutics, Inc.
$4.22
-1.2%Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
At a Glance
Live SnapshotProtara Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Protara Therapeutics, Inc. Cash Flow Statement
TARA • NASDAQ
| Protara Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||
-57.4M | -44.6M | -40.4M | -66M | -47.3M | -34M | -15M | -20.7M | -30M | -28.5M | -21.4M | -3.3M | -7.9M | -8M | |
362K | 332K | 341K | 248K | 117K | 196K | 279K | 115K | 148K | 123K | 57K | 30K | 27K | 57K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -9.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
3.8M | 4.1M | 6.1M | 6.7M | 10.4M | 9.7M | 943K | 3.4M | 925.0 | 3.3M | 2.2M | 459K | 0.0 | 0.0 | |
-173K | 324K | 569K | 32M | 1.7M | 9.9M | -4K | -76K | 3.4M | 3.7M | 3.6M | -7.2M | 821K | 243K | |
-2.9M | 4M | -4.1M | 539K | 534K | 629K | -1.9M | -6M | 4.4M | 1.3M | 327K | 109K | 361K | -564K | |
-56.4M | -35.8M | -37.6M | -26.5M | -34.5M | -23.4M | -15.6M | -23.2M | -22.4M | -23.7M | -17.6M | -10M | -6.7M | -8.2M | |
INVESTING ACTIVITIES | ||||||||||||||
-94K | -63K | -45K | -120K | -596K | -884K | -16K | -119K | -35K | -271K | -198K | -51K | -10K | -67K | |
(0.0) | (0.0) | (0.0) | -15.1K | (97.6K) | (3.7M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (65K) | (33K) | |
-204.6M | -29.4M | -12.2M | -43.6M | -124.7M | (0.0) | (0.0) | -15.4M | -32.9M | -39.8M | -88.6M | -35M | -3.9M | -8.7M | |
65.2M | 48.6M | 65.3M | 58.6M | 27.2M | 0.0 | 2.5M | 34M | 16.9M | 59.9M | 77.5M | 22.5M | 6.6M | 16.1M | |
0.0 | 0.0 | 0.0 | 15.1K | -97.6K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2M | 0.0 | 0.0 | -1K | |
-139.5M | (19.2M) | (53.1M) | (15M) | -98.2M | (2.8M) | (2.5M) | (18.4M) | -16.1M | (19.9M) | -11.3M | -12.5M | (2.7M) | (7.4M) | |
FINANCING ACTIVITIES | ||||||||||||||
82.9M | 136M | -91K | -90K | -228K | 87.9M | 500K | 2.9M | 1.5M | 208K | 163K | 88.5M | 21K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.3M | -9K | |
(0.0) | (0.0) | -91K | -90K | -228K | (0.0) | (0.0) | (0.0) | (0.0) | (208K) | (163K) | (0.0) | (0.0) | (0.0) | |
-185K | 3.9M | 0.0 | 0.0 | 0.0 | 11.6M | 0.0 | 132K | 21.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
82.7M | 139.9M | -91K | -90K | -228K | 189.4M | 500K | 3M | 23M | 208K | 163K | 88.5M | 4.4M | -9K | |
CASH FLOW SUMMARY | ||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -500K | 22K | 180K | -76K | -75K | 0.0 | 0.0 | 0.0 | |
-113.1M | 123.2M | 15.5M | -11.6M | -132.9M | 168.8M | -13.2M | -1.8M | -15.2M | -3.6M | -28.8M | 66M | 0.0 | 0.0 | |
163.5M | 40.3M | 24.9M | 36.5M | 169.4M | 564K | 19.4M | 21.2M | 36.4M | 40M | 68.8M | 2.8M | 2.4M | 0.0 | |
50.4M | 163.5M | 40.3M | 24.9M | 36.5M | 169.4M | 6.2M | 19.4M | 21.2M | 36.4M | 40M | 68.8M | 2.8M | 2.4M | |
-56.5M | -35.9M | -37.6M | -26.6M | -35.1M | -24.3M | -15.7M | -23.4M | -22.4M | -24M | -17.8M | -10M | -6.7M | -8.3M |
SEC Filings
TARA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
S-3 S-3 N/A | May 14, 2026 | May 14, 2026 | ||
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 15, 2025 | December 15, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 04, 2025 | 2025 |
Related Guides
Continue your TARA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.